Terms: = Kidney tumors AND HOXD13, SPD, 3239, P35453, HOX4I AND Prognosis
3 results:
1. Prognostic Value of Serum Soluble PD-L1 in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab.
Wakita N; Hinata N; Bando Y; Hara T; Terakawa T; Furukawa J; Nakano Y; Fujisawa M
Anticancer Res; 2023 Feb; 43(2):841-847. PubMed ID: 36697079
[TBL] [Abstract] [Full Text] [Related]
2. Soluble PD-L1 as an early marker of progressive disease on nivolumab.
Mahoney KM; Ross-Macdonald P; Yuan L; Song L; Veras E; Wind-Rotolo M; McDermott DF; Stephen Hodi F; Choueiri TK; Freeman GJ
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131863
[TBL] [Abstract] [Full Text] [Related]
3. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
[TBL] [Abstract] [Full Text] [Related]